XOMA Royalty Corporation Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Acquisitions (Tables)

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2026

The total purchase consideration for Generation Bio, as of February 9, 2026, was as follows (in thousands):


Closing cash payment⁽¹⁾	$	29,008
CVR consideration adjustment⁽²⁾		4,583
Transaction costs		823
Total purchase consideration	$	34,414

(1)The closing cash payment was based on the total of 6,753,846 shares of Generation Bio common stock at a price of $4.2913 per share, and the cash payment of $25,000 for 39,860 shares of Generation Bio’s in-the-money options.

(2)The probable amount of the additional closing net cash contingent consideration was estimated at $2.5 million and the probable amount of CVR liability related to the Binney Lease security deposit was estimated at $2.1 million.

The following table shows the allocation of the purchase consideration based on the relative fair value of assets acquired and liabilities assumed by the Company as of February 9, 2026 (in thousands):


Cash and cash equivalents	$	35,712
Trade and other receivables, net		24
Prepaid expenses and other current assets		122
Short-term restricted cash		2,181
Long-term restricted cash		360
Accounts payable		(165)
Accrued and other current liabilities		(275)
Net assets acquired	$	37,959
Reconciliation of net assets acquired to total purchase consideration:
Net assets acquired	$	37,959
Less: Gain on the acquisition of Generation Bio		(3,545)
Total purchase consideration	$	34,414